J. Scott Wolchko - Apr 21, 2022 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role
President and CEO, Director
Signature
/s/ Cindy Tahl, as Attorney-in-Fact
Stock symbol
FATE
Transactions as of
Apr 21, 2022
Transactions value $
-$1,395,792
Form type
4
Date filed
4/25/2022, 04:11 PM
Previous filing
Jan 27, 2022
Next filing
Jul 25, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FATE Common Stock Options Exercise $81K +30K +6.95% $2.70 462K Apr 21, 2022 Direct F1
transaction FATE Common Stock Sale -$785K -22.7K -4.92% $34.57* 439K Apr 21, 2022 Direct F1, F2
transaction FATE Common Stock Sale -$145K -4.06K -0.93% $35.73* 435K Apr 21, 2022 Direct F1, F3
transaction FATE Common Stock Sale -$81.5K -2.22K -0.51% $36.70* 433K Apr 21, 2022 Direct F1, F4
transaction FATE Common Stock Sale -$38K -1K -0.23% $37.90* 432K Apr 21, 2022 Direct F1, F5
transaction FATE Common Stock Options Exercise $27K +10K +2.32% $2.70 442K Apr 22, 2022 Direct F1
transaction FATE Common Stock Sale -$316K -9.16K -2.07% $34.54* 432K Apr 22, 2022 Direct F1, F6
transaction FATE Common Stock Sale -$29.5K -838 -0.19% $35.15* 432K Apr 22, 2022 Direct F1, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FATE Stock Option (Right to Buy) Options Exercise -$81K -30K -39.35% $2.70 46.2K Apr 21, 2022 Common Stock 30K $2.70 Direct F1, F8
transaction FATE Stock Option (Right to Buy) Options Exercise -$27K -10K -21.62% $2.70 36.2K Apr 22, 2022 Common Stock 10K $2.70 Direct F1, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020.
F2 Represents the weighted average sale price of the shares sold from $34.22 to $35.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 7.
F3 Represents the weighted average sale price of the shares sold from $35.29 to $36.25 per share.
F4 Represents the weighted average sale price of the shares sold from $36.29 to $37.08 per share.
F5 Represents the weighted average sale price of the shares sold from $37.70 to $38.38 per share.
F6 Represents the weighted average sale price of the shares sold from $34.04 to $35.03 per share.
F7 Represents the weighted average sale price of the shares sold from $35.04 to $35.29 per share.
F8 This option is fully vested.